Clinical characteristics and management of methamphetamine-associated cardiomyopathy: State-of-the-art review

Pavan K.V. Reddy, Tien M.H. Ng, Esther E. Oh, Gassan Moady, Uri Elkayam

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Methamphetamine-associated cardiomyopathy (MACM) is an increasingly recognized disease entity in the context of a rapidly spreading methamphetamine epidemic. MACM may afflict individuals with a wide range of ages and socioeconomic backgrounds. Presentations can vary greatly and may involve several complications unique to the disease. Given the public health significance of this disease, there is a relative dearth of consensus material to guide clinicians in understanding, diagnosing, and managing MACM. This review therefore aims to: (1) describe pathologic mechanisms of methamphetamine as they pertain to the development, progression, and prognosis of MACM, and the potential to recover cardiac function; (2) summarize existing data from epidemiologic studies and case series in an effort to improve recognition and diagnosis of the disease; (3) guide short-and long-term management of MACM with special attention to expected or potential sequelae of the disease; and (4) highlight pivotal unanswered questions in need of urgent investigation from a public health perspective.

Original languageEnglish
Article numbere016704
JournalJournal of the American Heart Association
Issue number11
StatePublished - 2 Jun 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 The Authors.


  • Cardiomyopathy
  • Diagnosis
  • Heart failure
  • Management
  • Methamphetamine


Dive into the research topics of 'Clinical characteristics and management of methamphetamine-associated cardiomyopathy: State-of-the-art review'. Together they form a unique fingerprint.

Cite this